School of Ophthalmology and Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
School of Ophthalmology and Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China; State Key Laboratory of Optometry, Ophthalmology and Vision Science, Wenzhou, Zhejiang, China.
Carbohydr Polym. 2021 Feb 1;253:117216. doi: 10.1016/j.carbpol.2020.117216. Epub 2020 Oct 13.
Uveitis is one of the most popular blind-causing eye diseases worldwide. Adalimumab (ADA) is used for the uveitis treatment through systemic or intravitreal injection at the expense of systemic side effects and increased medical risks. Although eye drops, a non-invasive topical treatment, could be a potential strategy to reduce side effects, it remains challenging to apply due to limited bioavailability mainly linked to poor retention time and permeation capacity for eye biological barriers. Here, we reported hydrogel eye drops composed of low-deacetylated chitosan and β-glycerophosphate as an ADA carrier and tested its toxicity, tolerability, intraocular permeability, and efficacy of non-invasive treatment for uveitis. It's found the ADA-loaded hydrogel eye drops were more efficient than free ADA both in permeation rate and clinical efficacy for uveitis, Overall, this study provides a friendly non-invasive strategy to improve drug permeation rate and uveitis treatment efficacy, which may be valuable to clinically ophthalmic medication.
葡萄膜炎是全球最常见的致盲眼病之一。阿巴西普（ADA）通过全身或玻璃体内注射用于治疗葡萄膜炎，但会产生全身副作用和增加医疗风险。尽管眼药水是一种非侵入性的局部治疗方法，可以降低副作用，但由于生物利用度有限，主要与眼部生物屏障的滞留时间和渗透能力差有关，因此应用仍然具有挑战性。在这里，我们报告了由低脱乙酰度壳聚糖和β-甘油磷酸组成的水凝胶眼药水作为 ADA 载体，并测试了其毒性、耐受性、眼内通透性和非侵入性治疗葡萄膜炎的疗效。结果发现，载 ADA 的水凝胶眼药水在渗透速率和葡萄膜炎的临床疗效方面均优于游离 ADA。总的来说，这项研究提供了一种友好的非侵入性策略，可提高药物渗透速率和葡萄膜炎治疗效果，这对于临床眼科用药可能具有重要价值。
